Skip to main content

Donor T Cells for Immune Control

Objective

Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD). Therefore, this treatment is still associated with a high morbidity and mortality, as well as a high economic burden. Our previous EU FP6 project, ALLOSTEM, resulted in a number of achievements, including a ‘first in man’ clinical trial that used a highly innovative novel cell selection strategy (Streptamer technology) for the generation of non-ATMP (advanced therapy medicinal product) monovirus specific T cell products. Continuing from ALLOSTEM, we now aim to develop two novel Streptamer-based clinical cell selection processes and its corresponding cell products. A multispecific T cell product targeting several viruses and tumors as well as a primary regulatory T cell product targeting GvHD will be developed to market maturity. These two cell products will improve the outcome of allogeneic HSCT. A significant improvement in the outcome and this coupled with a significant reduction of the costs for a large number of patients in Europe will further broaden the application in other forms of cancer of this curative treatment. In order to achieve this goal we assembled a consortium led by the University Hospital of Würzburg with Prof. Einsele as scientific coordinator together with renowned clinical scientists in the field of HSCT (all key players in ALLOSTEM).

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/biological sciences/microbiology/virology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /medical and health sciences/clinical medicine/transplantation
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/emergency medicine/graft versus host disease

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Address
Josef-schneider-strasse 2
97080 Wurzburg
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 118 101
Administrative Contact
Anne Von Thun (Ms.)

Participants (5)

ANTHONY NOLAN
United Kingdom
EU contribution
€ 925 266
Address
Agincourt Road 75-87 Units 2-3 Heathgate Place
NW3 2NU London
Activity type
Research Organisations
Administrative Contact
Alejandro Madrigal (Prof.)
JUNO THERAPEUTICS GMBH
Germany
EU contribution
€ 2 531 268
Address
Rudolf-wissell-strass 28
37079 Goettingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lothar Germeroth (Dr.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 935 110
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Frederik Falkenburg (Prof.)
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Participation ended

Germany
EU contribution
€ 115 766
Address
Oskar Von Miller Ring 29
80333 Muenchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Birgit Fuchs (Mrs.)
ARTTIC
France
EU contribution
€ 57 025
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Dietz (Dr.)